AKR1B1 and cancer: Likewise, it has been reported that, for the inhibition of AKR1B1 on TNBC cancer cells (MDA-MB231 and SUM159), EP treatment and knockdown of AKR1B1 lead to an alteration in the level of EMT markers (up-regulation of E-cadherin and down-regulation of vimentin) and decreased cancer cell migration and invasion.